Jansitin

Sitagliptin, the active ingredient in Jansitin, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to lower blood glucose levels when used with diet and exercise. GNH USA supplies Jansitin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jansitin (sitagliptin) is used within the DPP‑4 inhibitor class to manage hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose when combined with diet and exercise. - Inadequate control with metformin alone: provides additional HbA1c reduction as monotherapy. - Combination therapy with other antidiabetic agents: enhances overall glycaemic control in patients requiring multi‑drug regimens.

Adverse reactions to sitagliptin may vary in frequency and severity.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat. - Dizziness: occasional light‑headedness. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia. - Bullous pemphigoid: rare blistering skin disorder. - Hypersensitivity: fever, eosinophilia, or organ involvement.

Before initiating sitagliptin therapy, consider the following safety measures. - Renal impairment: adjust dose or avoid in severe renal dysfunction. - Hepatic impairment: use with caution in moderate liver disease. - Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas. - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; dose adjustments may be needed. - Cardiovascular disease: no specific contraindication, but monitor overall risk profile. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycaemia; dose reduction required. - Strong DPP‑4 inhibitors (e.g., saxagliptin): additive effect increases risk of adverse events.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, potentially reducing sitagliptin exposure. - Digoxin: may increase digoxin levels; monitor serum concentrations. - Diuretics (e.g., thiazides): may enhance hypoglycaemic effect; observe blood glucose closely.